POLB: A Drug Target / Disease Biomarker (G5423)

Target Name: POLB

NCBI ID: G5423

POLB

POLB: A Drug Target / Disease Biomarker

POLB, also known as poly (L-伪-glutamyl) protein, is a protein that is expressed in various tissues throughout the body. It is a key regulator of cellular processes such as cell signaling, inflammation, and DNA replication. POLB has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, it has become an attractive target for drug development.

One of the key functions of POLB is its role in regulating the levels of Glutamyl-Proteinase (GAP) in cells. GAP is a protein that helps to break down other proteins, including those that are involved in signaling pathways. By regulating the levels of GAP, POLB helps to ensure that cells have access to the signaling proteins that are necessary for proper function.

In addition to its role in regulating GAP levels, POLB has also been shown to play a key role in the regulation of cellular signaling pathways. Many signaling pathways involve the formation of a protein-protein complex, which is critical for the regulation of cellular processes such as cell growth, differentiation, and inflammation. POLB has been shown to play a key role in the formation of these protein-protein complexes, as well as in the regulation of the interactions between signaling proteins.

Another function of POLB is its role in the regulation of DNA replication. During DNA replication, POLB helps to ensure that the genetic material of the cell is replicated accurately and completely. This is important for the maintenance of genetic diversity and for the development and progression of cancer.

In addition to its role in regulating DNA replication, POLB has also been shown to play a key role in the regulation of cell cycle progression. The cell cycle is the process by which cells divide and replicate their genetic material. POLB has been shown to play a key role in the regulation of the length and timing of cell cycle events, as well as in the regulation of the nuclear envelope.

The identification of POLB as a potential drug target comes from several studies. First, researchers found that high levels of POLB were associated with poor prognosis in patients with pancreatic cancer, a disease that is characterized by the formation of malignant tumors in the pancreas, the gland that produces insulin. Second, researchers found that inhibition of the activity of POLB, using a small molecule inhibitor, improved the growth of cancer cells in a culture dish. Third, researchers found that the levels of GLUTAMYL-PROLYGLUTAMYL (GAP) were increased in the pancreatic cancer tissue compared to the normal tissue, and that the inhibition of GAP activity improved the growth of pancreatic cancer cells.

In conclusion, POLB, also known as poly (L-伪-glutamyl) protein, is a protein that is expressed in various tissues throughout the body. It plays a key role in regulating cellular processes such as cell signaling, inflammation, and DNA replication. As a result, it has become an attractive target for drug development, particularly for the treatment of diseases characterized by the formation of malignant tumors, including cancer.

Protein Name: DNA Polymerase Beta

Functions: Repair polymerase that plays a key role in base-excision repair. Has 5'-deoxyribose-5-phosphate lyase (dRP lyase) activity that removes the 5' sugar phosphate and also acts as a DNA polymerase that adds one nucleotide to the 3' end of the arising single-nucleotide gap. Conducts 'gap-filling' DNA synthesis in a stepwise distributive fashion rather than in a processive fashion as for other DNA polymerases

The "POLB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets